title: The management of adolescents with neurogenic urinary tract and bowel dysfunction.
abstract: Most children with neurogenic bladder dysfunction arrive into adolescence with reasonably managed lower urinary tract function only to experience bladder and kidney function deterioration after puberty. The aim of this article is to identify issues that contribute to adverse changes in bladder and renal function during adolescence and to highlight strategies to preserve urinary tract integrity, social continence, patient autonomy, and independence. Surveillance of bladder function requires patient attendance at review appointments and compliance with treatment plans. While encouraging independence and treatment compliance the clinician also needs to consider altered mental concentrating ability and fine motor skills of these patients. A keen eye for imminent loss of patient compliance to treatment protocol should be the mainstay of each encounter during puberty and adolescence. Annual surveillance of adolescent neurogenic bladder patients facilitates early identification of risk factors for urinary tract deterioration. Investigations include renal and bladder ultrasonography, urodynamic study when indicated, substantiated by videocystometry when anatomical status dictates. Serum creatinine should be measured and renal scintigraphy performed when upper urinary tract dilation, renal scarring, or atrophy are suspected. Optimal management of adolescents with neurologic disease of the urinary tract included strategies to reduce elevated detrusor pressure, maintain bladder compliance, and maximize dryness. Antimuscarinic medications, botulinum toxin A, and surgical procedures are enhanced by bowel management regimens and regular nurse or urotherapist patient contact. Caring for the patient as a whole requires discussion of sexuality, fertility status, and behaviors that increase the risk of progressive urinary tract damage.
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands. l.m.o.dekort@umcutrecht.nl
authors.forename: L M O
authors.initials: LM
authors.lastname: de Kort
authors.forename: W F
authors.initials: WF
authors.lastname: Bower
authors.forename: L V
authors.initials: LV
authors.lastname: Swithinbank
authors.forename: D
authors.initials: D
authors.lastname: Marschall-Kehrel
authors.forename: T P V M
authors.initials: TP
authors.lastname: de Jong
authors.forename: S B
authors.initials: SB
authors.lastname: Bauer
mesh_terms: D000293:Adolescent; D000294:Adolescent Behavior; D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000503:physiopathology; D008591:Meningomyelocele / Q000150:complications; D055496:Neurogenic Bowel / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D010349:Patient Compliance; D011237:Predictive Value of Tests; D012307:Risk Factors; D012648:Self Care; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000503:physiopathology*; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D014563:Urodynamics; D014741:Video Recording
chemical_list: D015415:Biomarkers; D003404:Creatinine